Breast Cancer Diagnostics Market: as federal breast density notification and a lowered USPSTF screening age expand the eligible screening population, imaging volume is compounding with genomic recurrence-risk testing on the same patient pathway, so combined imaging-plus-genomic diagnostic revenue is outgrowing imaging alone, and acquisitions by larger diagnostics and imaging conglomerates are consolidating the AI-enabled vendor base.

The global breast cancer diagnostics market size was USD 7.84 Billion in 2025 and is expected to register a revenue CAGR of 7.4% during the forecast period.Market revenue growth is driven by factors such as the expanded screening-eligible population created by the lowered USPSTF recommended screening age, mandatory federal breast density notification, and accelerating adoption of genomic recurrence-risk testing.The first driving factor is the US Preventive Services Task Force's recommendation lowering the recommended screening start age from 50 to 40 years for women at average risk.This single guideline change substantially expanded the eligible screening population across primary care and breast imaging settings nationwide, reversing more than a decade of guidance that had left screening timing in a woman's forties as an individual decision.The second driving factor is the FDA's Mammography Quality Standards Act amended regulations requiring every US mammography facility to disclose a standardised breast density classification.This replaced a fragmented landscape previously governed by 39 individual state laws, structurally embedding dense-tissue awareness and supplemental imaging referral into national screening infrastructure for the first time.The third driving factor is accelerating adoption of genomic recurrence-risk testing alongside imaging-based diagnosis.Myriad Genetics reported full-year revenue of USD 838 million, an 11% year-over-year increase, driven by its MyRisk test combining BRCA1/2 genetic analysis with recurrence-risk scoring.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single genomic recurrence-risk platform widens its addressable revenue every time it adds a new post-diagnosis application on the same patient relationship, without the laboratory having to win a new referral pathway from zero.Once a health system routes a newly diagnosed patient to a genomic recurrence-risk test for treatment selection, each additional application such as molecular residual disease monitoring adds incremental testing revenue on the same patient without requiring a new imaging referral or a new ordering physician relationship, so platform revenue compounds as the post-diagnosis testing menu grows around the original recurrence-risk test.As a result, demand and revenue share are concentrating around genomic testing platforms that span initial recurrence-risk scoring through post-treatment monitoring, that hold the broadest guideline inclusion, and the forecast tilts toward these full-pathway platforms rather than single-purpose recurrence-risk tests alone.For instance, in February 2025, Myriad Genetics, United States, announced a five-year strategic alliance with the University of Texas MD Anderson Cancer Center to evaluate its Precise molecular residual disease assay across breast and other cancer types, extending the same genomic testing relationship from initial diagnosis into post-treatment recurrence monitoring without a new laboratory contract for the monitoring service.These are some of the key factors driving revenue growth of the market.

Because ultrasound, breast MRI, and contrast-enhanced mammography frequently require separate prior authorisation even after a federally mandated dense-breast notification directs patients to discuss additional screening, patients face out-of-pocket costs that deter follow-up imaging.

Screening access is a second constraint, because only 13.5% of women eligible for the CDC's National Breast and Cervical Cancer Early Detection Program received programme-funded screening between 2020 and 2021, so low-income and uninsured women remain structurally underserved despite genomic and imaging innovation.

Capital constraints at independent and rural imaging centres are a third constraint, since upgrading from 2D to 3D digital breast tomosynthesis systems carries a substantial premium over conventional mammography units, so smaller providers lag the technology adoption curve that larger hospital systems can afford.

These factors substantially limit breast cancer diagnostics market growth over the forecast period.

The clearest driver of demand is the US Preventive Services Task Force's recommendation lowering the recommended screening start age from 50 to 40 years for women at average risk. A screening guideline only converts into diagnostic revenue if imaging capacity and referral infrastructure can absorb the expanded population, and Hologic's installed tomosynthesis base was already positioned to absorb higher national volume when the guideline changed, so imaging revenue growth followed the policy change with minimal capacity lag. Hologic reported that its Breast Health segment, anchored by its 3D Dimensions tomosynthesis platform, generated USD 1,522.9 Million in fiscal year 2024 revenue. The recent record shows the pace. In November 2025, GE HealthCare, United States, received FDA Premarket Authorization for Pristina Recon DL, a deep learning mammography reconstruction technology, and enforcement of the FDA's amended Mammography Quality Standards Act density notification requirement began in September 2024, embedding dense-tissue disclosure into every US mammography report. The effect on the market is that both primary screening volume and supplemental imaging referral rates are structurally higher than before the 2024 policy changes. These are some of the key factors driving revenue growth of the market.

The second driver is the acquisition of independent AI-enabled breast diagnostics developers by larger imaging and diagnostics companies. Independent AI breast imaging vendors increasingly lack the commercial distribution scale to reach the expanded USPSTF-eligible screening population on their own, and larger imaging networks and diagnostics companies have the installed base to deploy AI tools at scale immediately, so acquisition has become the fastest path to distribution for point-solution AI developers. Two of the sector's most closely watched independent platforms changed ownership within a twelve-month span, concentrating a meaningfully larger share of AI-powered breast cancer detection volume inside two acquirers. In July 2025, RadNet, United States, completed its acquisition of iCAD, uniting iCAD's ProFound Breast Health Suite with RadNet's DeepHealth SmartMammo platform to expand AI-powered mammogram analysis to more than 10 million exams annually, and in November 2025 Abbott entered a definitive agreement to acquire Exact Sciences, owner of the Oncotype DX breast recurrence-risk test, in a transaction valued at approximately USD 21 Billion. The effect on the market is that AI-enabled breast imaging and genomic recurrence-risk testing revenue is shifting toward platforms backed by larger diagnostics and imaging conglomerates rather than independent point-solution vendors. These are some of the key factors driving revenue growth of the market.

“RadNet's acquisition of iCAD alone expanded AI-powered mammogram analysis capacity from roughly 1.9 million to more than 10 million exams annually under a single platform.”

The third driver is the clinical and guideline momentum behind genomic recurrence-risk testing as a standard component of the post-diagnosis pathway. A recurrence-risk test only changes prescribing behaviour once it is included in major treatment guidelines with outcomes evidence behind it, and Oncotype DX has now cleared that bar across multiple guideline bodies, so ordering physicians increasingly treat genomic testing as a default step rather than an optional add-on. The Oncotype DX Breast Recurrence Score test surpassed 2 million patients tested worldwide, and Exact Sciences presented ten abstracts on the test's clinical and economic impact at the December 2025 San Antonio Breast Cancer Symposium. In June 2025, Clairity, United States, received FDA De Novo authorisation for Clairity Breast, the first AI platform to predict five-year breast cancer risk directly from a standard screening mammogram, extending genomic-style risk stratification into the imaging pathway itself. The effect on the market is that diagnostic spend per patient is rising as genomic and AI-based risk assessment stack on top of, rather than substitute for, imaging-based screening. These are some of the key factors driving revenue growth of the market.

However, the breast cancer diagnostics market faces severe adoption constraints from supplemental imaging reimbursement fragmentation and persistent screening access gaps.

Because breast MRI, contrast-enhanced mammography, and screening ultrasound frequently require separate prior authorisation processes even after a federally mandated dense-breast notification directs patients to discuss additional screening, patients face out-of-pocket costs that can deter the very follow-up imaging the notification is designed to prompt.

Screening access is a second constraint, because the CDC's National Breast and Cervical Cancer Early Detection Program reached only 13.5% of eligible women during 2020 to 2021, so low-income and uninsured populations remain structurally underserved even as breast cancer incidence continues to rise among US women according to American Cancer Society data.

Capital constraints at independent and rural imaging centres are the third constraint, since upgrading from 2D to 3D digital breast tomosynthesis carries a substantial premium over conventional mammography units, so the technology gap between well-capitalised hospital systems and independent or rural providers is widening rather than narrowing.

These factors substantially limit breast cancer diagnostics market growth over the forecast period.

Based on regional analysis, the breast cancer diagnostics market in North America accounted for the largest revenue share in 2025, at approximately 45% of global market revenue. The United States drives the regional position through the 2024 federal screening and density disclosure regulatory changes and the commercial presence of Hologic, Exact Sciences, and Myriad Genetics maintaining direct US breast imaging and genomic testing sales infrastructure. Abbott's pending acquisition of Exact Sciences and RadNet's completed acquisition of iCAD both reinforce the region's position as the centre of AI-enabled breast diagnostics consolidation. The concentration of FDA-cleared and FDA-authorised breast diagnostic platforms in the United States also means new products and indications are often launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate in the global breast cancer diagnostics market over the forecast period.

Germany, France, and the United Kingdom represent the three largest national breast cancer diagnostics markets in Europe. National breast screening programmes operated by the NHS and equivalent statutory health insurance-funded programmes in Germany and France provide population-level mammography infrastructure that differs structurally from the predominantly provider-initiated US screening model, with genomic recurrence-risk test reimbursement decided through national health technology assessment bodies on a country-by-country basis. The result is steady rather than rapid growth, shaped more by national HTA reimbursement timelines than by underlying screening demand, which the expanded USPSTF-style guidance in the United States has already outpaced.

The market in Asia Pacific is expected to register a rapid revenue growth rate in the global breast cancer diagnostics market over the forecast period.

China, Japan, and South Korea represent the three largest national breast cancer diagnostics markets within the region. The Oncotype DX test's documented international clinical adoption in Japan reflects active commercial expansion of genomic recurrence-risk testing into Asia-Pacific oncology markets, alongside rising breast imaging infrastructure investment across tertiary hospital networks in urban China and South Korea. Growing physician awareness of genomic recurrence-risk testing as a complement to imaging-based diagnosis is expanding the addressable market for combined imaging-plus-genomic pathways faster than in the already-established North American market.

The market in Latin America is expected to register a moderate revenue growth rate in the global breast cancer diagnostics market over the forecast period.

Brazil and Mexico represent the two largest national breast cancer diagnostics markets in the region, with access to digital breast tomosynthesis and genomic recurrence-risk testing concentrated at a small number of private and academic oncology referral centres in São Paulo, Mexico City, and Buenos Aires. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have raised freight and import costs for imaging system components and genomic testing reagent kits entering Brazilian distribution channels, a disruption that has run through 2026 and maintains pricing pressure for imported diagnostic platforms beyond the largest private referral centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate in the global breast cancer diagnostics market over the forecast period.

Saudi Arabia and the United Arab Emirates represent the primary commercial markets within the GCC. Saudi Arabia is the most established market on the continent for tertiary breast cancer screening and genomic testing referral pathways, anchored by King Faisal Specialist Hospital and Research Centre in Riyadh, while the wider Gulf and North African sub-regions are still building the basic tomosynthesis screening infrastructure the expanded USPSTF-style guidance assumes.